Experimental group:venetoclax + azacitidine

2 trials

Sponsors

The First Affiliated Hospital of Zhejiang University Medical College, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Conditions

AML patients with NPM1 or IDH1/IDH2 mutations who are eligible for intensive chemotherapyMyelodysplastic Syndrome

Phase 4

Prospective, single-arm, multicenter clinical study of the efficacy and safety of venetoclax combined with azacitidine in the treatment of adult patients with higher-risk myelodysplastic syndrome

RecruitingChiCTR2200056993

The First Affiliated Hospital of Zhejiang University Medical CollegeMyelodysplastic Syndrome

Start: 2022-02-15Updated: 2023-09-18

Unknown Phase

A Prospective, Multicenter, Randomized, Open-Label, Non-Inferiority Clinical Trial of Venetoclax Combined with Azacitidine (VA Regimen) versus Conventional "3+7" Regimen in Newly Diagnosed AML Patients with NPM1 or IDH1/IDH2 Mutations

Active, not recruitingChiCTR2600128218

Ruijin Hospital, Shanghai Jiao Tong University School of MedicineAML patients with NPM1 or IDH1/IDH2 mutations who are eligible for intensive chemotherapy

Start: 2026-07-16Updated: 2026-07-20